Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13380801 | 0.87 | MAPT (0.50) | NPC1RAB9AMAPTSMN1; SMN2ELANE | |
| SCHEMBL3319281 | 0.87 | GSK3B (0.49) | GSK3BPTPN1NPC1RAB9AERCC5 | |
| SCHEMBL13586884 | 0.85 | ELANE (0.39) | NPC1RAB9AMAPTSMN1; SMN2ELANE | |
| SCHEMBL12919164 | 0.85 | CA1 (0.46) | ELANE | |
| SCHEMBL862839 | 0.84 | MAPT (0.46) | NPC1RAB9AMAPTSMN1; SMN2HSD11B1 | |
| SCHEMBL2815643 | 0.84 | PPARA (0.47) | GSK3BPTPN1NPC1RAB9AMAPT | |
| SCHEMBL17070013 | 0.84 | ELANE (0.54) | ELANE | |
| SCHEMBL863103 | 0.84 | MAOB (0.46) | NPC1RAB9AMAPTSMN1; SMN2ELANE | |
| SCHEMBL5032713 | 0.80 | GSK3B (0.59) | GSK3BPTPN1 | |
| SCHEMBL21176731 | 0.80 | CES1 (0.50) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116858-B1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2020-11-11 | — | — | EP | disclosed |
| US-20180339993-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2018-11-29 | — | — | US | disclosed |
| US-10093678-B2 | Azaspiro derivatives as TRPM8 antagonists | RAQUALIA PHARMA INC. (JP) | 2018-10-09 | — | — | US | disclosed |
| EP-3116858-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RaQualia Pharma Inc. (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| WO-2015136947-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2015-09-17 | — | — | WO | disclosed |
| US-8143366-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2012-03-27 | — | — | US | disclosed |
| US-20100081782-A1 | ARYL CARBAMATE OLIGOMERS FOR HYDROLYZABLE PRODRUGS AND PRODRUGS COMPRISING SAME | EKWURIBE NNOCHIRI N | 2010-04-01 | — | — | US | disclosed |
| US-7335751-B2 | Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same | BIOCON LIMITED (IN) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | GSK3B 2725/4885PTPN1 1287/4885NPC1 459/4885 |
| US-10093678-B2 | Azaspiro derivatives as TRPM8 antagonists | TRPM8, TRPM7, TRPM5 | GSK3B 2725/4885PTPN1 1287/4885NPC1 459/4885 |
| US-20180339993-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM6 | GSK3B 2584/4885PTPN1 1277/4885NPC1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.